Article Link: Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients ...
FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
Article Link: FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson’s Disease Patients Sourc...
FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
Article Link: FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout Source:...
FDA Approves Tablet Formulation of Lynparza (olaparib) for Maintenance Treatment of Ovarian Cancer
Article Link: FDA Approves Tablet Formulation of Lynparza (olaparib) for Maintenance Treatment of Ovarian Cancer Source: FD...
FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
Article Link: FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia Source:...
CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension
Article Link: CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension Source: FDA New Drug App...
FDA Approves Medicines360's sNDA for Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years
Article Link: FDA Approves Medicines360’s sNDA for Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to F...
FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia
Article Link: FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia ...
FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C
Article Link: FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C Source: FDA New Drug Approvals
FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease
Article Link: FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease Source: FDA New Drug Approvals
